☰

Gregory M. Cote, Ph.D. - Publications

Affiliations: 
2004 Boston University, Boston, MA, United States 
Area:
Molecular Biology
Tree Info Similar researchers PubMed Report error

52 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Tap WD, Villalobos VM, Cote GM, Burris H, Janku F, Mir O, Beeram M, Wagner AJ, Jiang L, Wu B, Choe S, Yen K, Gliser C, Fan B, Agresta S, et al. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902492. PMID 32208957 DOI: 10.1200/Jco.19.02492  0.306
2020 Cote GM, DeLaney TF, Miao R, Schwab JH, Raskin K, Lozano Calderón S, Mullen JT, Haynes AB, Hornicek FJ, Chen Y, Choy E. Updated 5-year local control (LC), metastasis-free survival (MFS), and overall survival (OS) data from a phase I study of nilotinib plus radiation (RT) in high-risk chordoma. Journal of Clinical Oncology. 38: e23505-e23505. DOI: 10.1200/Jco.2020.38.15_Suppl.E23505  0.314
2020 Mellinghoff IK, Peters KB, Cloughesy TF, Burris III HA, Maher EA, Janku F, Cote GM, De La Fuente MI, Clarke JL, Le K, Liu L, Yuen M, Arnofsky M, Hassan I, Steelman L, et al. Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population. Journal of Clinical Oncology. 38: 2504-2504. DOI: 10.1200/Jco.2020.38.15_Suppl.2504  0.335
2020 Gounder MM, Stacchiotti S, Schoffski P, Cote GM, Villalobos VM, Jahan TM, Chen TW, Ratan R, Gupta AA, Dileo P, Agulnik M, Italiano A, Attia S, Mir O, Pressey JG, et al. Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma. Journal of Clinical Oncology. 38: 11564-11564. DOI: 10.1200/Jco.2020.38.15_Suppl.11564  0.324
2020 Nathenson M, Choy E, Carr ND, Hibbard HD, Mazzola E, Catalano PJ, Thornton KA, Morgan JA, Cote GM, Merriam P, Wagner AJ, Demetri GD, George S. Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort. Journal of Clinical Oncology. 38: 11559-11559. DOI: 10.1200/Jco.2020.38.15_Suppl.11559  0.346
2019 Cote GM, Choy E, Chen T, Marino-Enriquez A, Morgan J, Merriam P, Thornton K, Wagner AJ, Nathenson MJ, Demetri G, George S. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. European Journal of Cancer (Oxford, England : 1990). 126: 21-32. PMID 31896519 DOI: 10.1016/J.Ejca.2019.10.021  0.336
2019 Widemann BC, Lu Y, Reinke D, Okuno SH, Meyer CF, Cote GM, Chugh R, Milhem MM, Hirbe AC, Kim A, Turpin B, Pressey JG, Dombi E, Jayaprakash N, Helman LJ, et al. Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma. 2019: 7656747. PMID 31427883 DOI: 10.1155/2019/7656747  0.336
2019 Luke JJ, Sharma M, Sanborn RE, Cote GM, Bendell JC, Weiss GJ, Berezhnoy A, Sharma S, Moore PA, Bonvini E, Cali K, Baughman JE, Wigginton JM, Sumrow B. A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms. Journal of Clinical Oncology. 37: TPS2661-TPS2661. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps2661  0.327
2019 Cote GM, Chawla SP, Burgess MA, Thornton KA, Oldham RK, Okuno SH, Ballman KV, Matlow S, Barnett D, Attia S. CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on doxorubicin. Journal of Clinical Oncology. 37: TPS11077-TPS11077. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps11077  0.306
2019 Stacchiotti S, Schoffski P, Jones R, Agulnik M, Villalobos VM, Jahan TM, Chen TW, Italiano A, Demetri GD, Cote GM, Chugh R, Attia S, Gupta AA, Loggers ET, Van Tine B, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). Journal of Clinical Oncology. 37: 11003-11003. DOI: 10.1200/Jco.2019.37.15_Suppl.11003  0.348
2018 Daigle S, Stacchiotti S, Schöffski P, Villalobos V, Cote G, Chugh R, Chen TW, Jahan T, Loggers ET, Italiano A, Gupta A, Agulnik M, Attia S, Jones RL, van Tine BA, et al. Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii670. PMID 32137834 DOI: 10.1093/Annonc/Mdy304  0.3
2018 Cote GM, Barysauskas CM, DeLaney T, Schwab J, Raskin K, Lozano-Calderon S, Bernstein K, Mullen J, Haynes AB, Hornicek F, Chen YL, Choy E. A Phase I Study of Nilotinib plus Radiation in High-Risk Chordoma. International Journal of Radiation Oncology, Biology, Physics. PMID 30077789 DOI: 10.1016/J.Ijrobp.2018.07.2013  0.328
2018 Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, Bullock A, Rock E, Elekes A, Lin C, Kostic D, Ohi N, Rasco D, Papadopoulos KP, Patnaik A, ... ... Cote GM, et al. A First-in-Human Phase 1 Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. The Oncologist. PMID 29511132 DOI: 10.1634/Theoncologist.2017-0325  0.315
2018 Shih AR, Cote GM, Chebib I, Choy E, DeLaney T, Deshpande V, Hornicek FJ, Miao R, Schwab JH, Nielsen GP, Chen YL. Clinicopathologic characteristics of poorly differentiated chordoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 29483606 DOI: 10.1038/S41379-018-0002-1  0.309
2018 Kalra M, Cote GM, Heist RS, Spittler AJ, Yu S, Hitron M, Loehrer PJ. A phase 1b study of napabucasin (NAPA) + weekly paclitaxel (PTX) in patients (pts) with advanced thymoma and thymic carcinoma. Journal of Clinical Oncology. 36: e20578-e20578. DOI: 10.1200/Jco.2018.36.15_Suppl.E20578  0.312
2017 Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z. Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. Scientific Reports. 7: 43941. PMID 28262798 DOI: 10.1038/Srep43941  0.333
2017 Hitron M, Spittler AJ, Cote GM, Heist RS, Kossler K, Li W, Li Y, Li C, Loehrer PJ. A phase 1b study of napabucasin plus weekly paclitaxel in patients with advanced thymoma and thymic carcinoma. Journal of Clinical Oncology. 35: e20001-e20001. DOI: 10.1200/Jco.2017.35.15_Suppl.E20001  0.345
2017 Becerra C, Hanna WT, Richey SL, Cote GM, Laurie SA, Langleben A, Gao Y, Li W, Li Y, Hitron M, Li C. A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated non-squamous non-small cell lung cancer. Journal of Clinical Oncology. 35: 9052-9052. DOI: 10.1200/Jco.2017.35.15_Suppl.9052  0.364
2017 Cote GM, Edenfield WJ, Laurie SA, Chau NG, Becerra C, Spira AI, Li Y, Li W, Hitron M, Li C. A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma. Journal of Clinical Oncology. 35: 6036-6036. DOI: 10.1200/Jco.2017.35.15_Suppl.6036  0.368
2017 Cote GM, Chau NG, Spira AI, Edenfield WJ, Laurie SA, Richards DA, Richey SL, Gao Y, Li Y, Li W, Hitron M, Li C. A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer. Journal of Clinical Oncology. 35: 6032-6032. DOI: 10.1200/Jco.2017.35.15_Suppl.6032  0.342
2017 Becerra C, Garcia AA, Hays JL, Method MW, Richey SL, Langleben A, Richards DA, Cote GM, Kossler K, Li W, Li Y, Hitron M, Li C. A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer. Journal of Clinical Oncology. 35: 5548-5548. DOI: 10.1200/Jco.2017.35.15_Suppl.5548  0.361
2017 Gounder MM, Stacchiotti S, Schöffski P, Attia S, Italiano A, Jones R, Demetri GD, Blakemore S, Clawson A, Daigle S, Ribich S, Roche M, Rodstrom J, Ho PT, Cote GM. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology. 35: 11058-11058. DOI: 10.1200/Jco.2017.35.15_Suppl.11058  0.351
2017 Schoffski P, Agulnik M, Stacchiotti S, Davis LE, Villalobos VM, Italiano A, George S, Cote GM, Blakemore S, Clawson A, Daigle S, Ribich S, Roche M, Rodstrom J, Ho PT, et al. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950). Journal of Clinical Oncology. 35: 11057-11057. DOI: 10.1200/Jco.2017.35.15_Suppl.11057  0.348
2017 Choy E, Cote GM, Michaelson MD, Wirth L, Gainor JF, Sequist LV, Sullivan RJ, Fidias PM, Shaw A, Heist RS. Abstract CT129: Phase 2 study of cabozantinib in patients with non-breast, non-prostate cancer with bone metastasis Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct129  0.318
2016 Shen JK, Cote GM, Gao Y, Choy E, Mankin HJ, Hornicek FJ, Duan Z. Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. Scientific Reports. 6: 25239. PMID 27125524 DOI: 10.1038/Srep25239  0.32
2016 Gao Y, Liao Y, Shen JK, Feng Y, Choy E, Cote G, Harmon D, Mankin HJ, Hornicek FJ, Duan Z. Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society. PMID 26790551 DOI: 10.1002/Jor.23173  0.317
2016 Bekaii-Saab TS, Mikhail S, Langleben A, Becerra C, Jonker DJ, Asmis TR, Cote GM, Wu CS, Kwak EL, Spira AI, Braiteh FS, Richey SL, Hume S, Hitron M, Li C. A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer. Journal of Clinical Oncology. 34: 196-196. DOI: 10.1200/Jco.2016.34.4_Suppl.196  0.354
2016 Agulnik M, Tannir NM, Pressey JG, Gounder MM, Cote GM, Roche M, Doleman S, Blakemore SJ, Clawson A, Daigle S, Tang J, Ho PT, Demetri GD. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma. Journal of Clinical Oncology. 34: TPS11071-TPS11071. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps11071  0.301
2016 Becerra C, Spira AI, Conkling PR, Richey SL, Hanna WT, Cote GM, Heist RS, Langleben A, Laurie SA, Edenfield WJ, Kossler K, Hume S, Li Y, Hitron M, Li C. A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer. Journal of Clinical Oncology. 34: 9093-9093. DOI: 10.1200/Jco.2016.34.15_Suppl.9093  0.312
2016 Garcia AA, Hays JL, Cote GM, Becerra C, Langleben A, Lau SK, Roman LD, McCormick CC, Richards DA, Braiteh FS, Yimer HA, Richey SL, Edenfield WJ, Kossler K, Hume S, et al. A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer. Journal of Clinical Oncology. 34: 5578-5578. DOI: 10.1200/Jco.2016.34.15_Suppl.5578  0.314
2015 Liao Y, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z. Clinical and biological significance of PIM1 kinase in osteosarcoma. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society. PMID 26687194 DOI: 10.1002/Jor.23134  0.374
2015 Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, Cote GM, Wagner AJ, Morgan JA, Sirisawad M, Mani C, Hornicek FJ, Duan Z, Demetri GD. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 121: 1223-30. PMID 25536954 DOI: 10.1002/Cncr.29175  0.317
2015 Jonker DJ, Laurie SA, Cote GM, Flaherty K, Fuchs CS, Chugh R, Smith DC, Edenfield WJ, Conkling PR, Mier JW, Goodwin RA, Kwak EL, Abrams TA, Goel R, Cleary JM, et al. Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. Journal of Clinical Oncology. 33: 3615-3615. DOI: 10.1200/Jco.2015.33.15_Suppl.3615  0.342
2015 Cote G, Papadopoulos K, Patnaik A, Rascoe D, Smith L, Bullock A, Flaherty K, Shapiro G, Berlin J, Monga M, Habermann T, Witzig T, Lin C, Tsai L, Elekes A, et al. Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B118  0.328
2014 Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GD. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. Bmc Cancer. 14: 813. PMID 25374341 DOI: 10.1186/1471-2407-14-813  0.356
2014 Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. Bmc Cancer. 14: 681. PMID 25236161 DOI: 10.1186/1471-2407-14-681  0.306
2014 Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunology Research. 2: 690-8. PMID 24866169 DOI: 10.1158/2326-6066.Cir-13-0224  0.309
2014 Yang X, Yang P, Shen J, Osaka E, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925 British Journal of Cancer. 110: 2896-2904. PMID 24853187 DOI: 10.1038/Bjc.2014.254  0.304
2014 Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, Nielsen GP, Yang C, Zhang C, Mankin H, Hornicek FJ, Borger DR, Duan Z. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. Plos One. 9: e93996. PMID 24695632 DOI: 10.1371/Journal.Pone.0093996  0.352
2014 Jia B, Choy E, Cote G, Harmon D, Ye S, Kan Q, Mankin H, Hornicek F, Duan Z. Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer Letters. 342: 104-12. PMID 24007862 DOI: 10.1016/J.Canlet.2013.08.040  0.31
2013 Cote GM, Choy E. Role of epigenetic modulation for the treatment of sarcoma. Current Treatment Options in Oncology. 14: 454-64. PMID 23749746 DOI: 10.1007/S11864-013-0239-3  0.323
2013 Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. The New England Journal of Medicine. 368: 876. PMID 23445109 DOI: 10.1056/NEJMc1215887  0.421
2012 Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. The New England Journal of Medicine. 367: 2150-3. PMID 23190227 DOI: 10.1056/Nejmcibr1203156  0.506
2011 Cote GM, Feng Y, Sohani AR, Roberts ZJ, Colpo A, Hochberg FH, Chen YA, Michaelson JS, Neuberg D, Abramson JS, Hochberg EP. Secondary Central Nervous System Lymphoma: A Single Center Experience Blood. 118: 5181-5181. DOI: 10.1182/Blood.V118.21.5181.5181  0.303
2009 Moondra V, Sarma S, Buxton T, Safa R, Cote G, Storer T, Lebrasseur NK, Sawyer DB. Serum Neuregulin-1beta as a Biomarker of Cardiovascular Fitness. The Open Biomarkers Journal. 2: 1-5. PMID 20634924 DOI: 10.2174/1875318300902010001  0.703
2009 Pentassuglia L, Graf M, Lane H, Kuramochi Y, Cote G, Timolati F, Sawyer DB, Zuppinger C, Suter TM. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Experimental Cell Research. 315: 1302-12. PMID 19331811 DOI: 10.1016/J.Yexcr.2009.02.001  0.546
2009 Miller TA, Icli B, Cote GM, Lebrasseur NK, Borkan SC, Pimentel DR, Peng X, Sawyer DB. Palmitate alters neuregulin signaling and biology in cardiac myocytes. Biochemical and Biophysical Research Communications. 379: 32-7. PMID 19070592 DOI: 10.1016/J.Bbrc.2008.11.150  0.711
2005 Cote GM, Miller TA, Lebrasseur NK, Kuramochi Y, Sawyer DB. Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Experimental Cell Research. 311: 135-46. PMID 16185687 DOI: 10.1016/J.Yexcr.2005.08.017  0.537
2005 Miller TA, LeBrasseur NK, Cote GM, Trucillo MP, Pimentel DR, Ido Y, Ruderman NB, Sawyer DB. Oleate prevents palmitate-induced cytotoxic stress in cardiac myocytes. Biochemical and Biophysical Research Communications. 336: 309-15. PMID 16126172 DOI: 10.1016/J.Bbrc.2005.08.088  0.503
2004 Kuramochi Y, Cote GM, Guo X, Lebrasseur NK, Cui L, Liao R, Sawyer DB. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. The Journal of Biological Chemistry. 279: 51141-7. PMID 15385548 DOI: 10.1074/Jbc.M408662200  0.55
2004 Tanaka Y, Koido S, Xia J, Ohana M, Liu C, Cote GM, Sawyer DB, Calderwood S, Gong J. Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion. Journal of Immunology (Baltimore, Md. : 1950). 172: 7848-58. PMID 15187169 DOI: 10.4049/Jimmunol.172.12.7848  0.469
2003 Lebrasseur NK, Coté GM, Miller TA, Fielding RA, Sawyer DB. Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. American Journal of Physiology. Cell Physiology. 284: C1149-55. PMID 12519750 DOI: 10.1152/Ajpcell.00487.2002  0.498
Show low-probability matches.